EpiCept Corp. (EPCT: OTCQX U.S.) | EPICEPT REPORTS SECOND

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EpiCept Corp. (EPCT: OTCQX U.S.) | EPICEPT REPORTS SECOND QUARTER 2013 OPERATING AND FINANCIAL RESULTS

Contacts

 

EpiCept Corporation:

777 Old Saw Mill River Road

Tarrytown, NY 10591

Robert W. Cook

(914) 606-3500

rcook@epicept.com

Media Contact

Feinstein Kean Healthcare

Greg Kelley

(404) 836-2302

gregory.kelley@fkhealth.com

 

 

 

 

 

EpiCept Reports Second Quarter 2013 Operating and Financial Results

Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals

 

TARRYTOWN, N.Y. (August 1, 2013) ? EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three and six months ended June 30, 2013, and provided an update on the Company?s upcoming merger with Immune Pharmaceuticals, Ltd. (Immune).

 

Robert Cook, Interim President and CEO of EpiCept, commented, ?Our excitement about the merger between EpiCept and Immune is growing as we get closer to the stockholder vote on August 6 and to the closing of the merger transaction shortly after obtaining stockholder approval. We believe the combination of our companies will benefit both sets of shareholders and will in particular provide EpiCept?s stockholders with a great opportunity to participate in the antibody therapeutics sector, one of the most dynamic in the biotech industry. We look forward to our transition into a new company, Immune Pharmaceuticals, Inc, focused on these cutting-edge products.?

 

Mr. Cook added, ?We are very pleased with the results of the vote to date with more than 93% of the votes cast so far in favor of the proposals.   We fully anticipate that our Special Meeting of Stockholders on August 6 will result in our meeting the final conditions to the closing of this important transaction.?

 

Merger Update

 

In November 2012, following the approval of the companies? respective boards of directors, EpiCept signed a merger agreement with Immune Pharmaceuticals Ltd., a private company based in Herzliya-Pituach, Israel and New York, NY. The terms of the merger agreement provide that, upon the closing of the transaction, EpiCept will issue shares of its common stock to Immune shareholders in exchange for all outstanding shares of Immune and issue options and warrants to purchase shares of its common stock in exchange for certain options and warrants to purchase shares of Immune.   EpiCept stockholders will own approximately 19% of the combined company and Immune shareholders will own approximately 81%, calculated on an adjusted fully diluted basis. The merger ratio initially excludes the exercise or conversion of certain EpiCept options and warrants whose exercise/conversion prices equal or exceed $0.60 per EpiCept share. 

 

EpiCept mailed a definitive proxy in June 2013 to its stockholders seeking approval for a reverse stock split of 1:40.   The reverse split should cause an increase in the price per share of EpiCept's common stock, and will support EpiCept?s near term goal of relisting its shares on a U.S. national securities exchange.   EpiCept is also seeking approval for a change in the name of the company to Immune Pharmaceuticals, Inc. (IPI).   The companies currently anticipate that following receipt of stockholder approval the merger transaction will close during August 2013.

 

Financial Condition

 

EpiCept had approximately $0.2 million in cash and cash equivalents as of June 30, 2013. In addition, EpiCept?s lender has restricted $0.6 million of the Company?s cash, with which EpiCept is required to make monthly interest payments on its senior secured term loan. The Company received $0.5 million of net cash from Immune during the first six months of 2013 through the issuance of approximately 3.8 million shares of EpiCept common stock and an additional $0.6 million by entering into a loan pursuant to the merger agreement with Immune.     

 

Immune has raised $4.1 million since the beginning of 2013 in order to fund the associated merger costs and the on-going operations of both Immune and EpiCept through the merger closing.   IPI intends to obtain funding to support approximately 18 months of operations.

 

EpiCept?s obligations under its outstanding loan with MidCap Financial LLC are expected to be assumed by IPI upon or shortly after the merger closing.     EpiCept and Immune have agreed to indicative terms and conditions offered by MidCap Financial related to the loan?s restructure.   In July 2013, EpiCept and MidCap executed a Second Amendment to the Loan and Security Agreement in which the parties agreed that interest payments will continue to be made monthly and one half of the cash escrow will be returned to EpiCept upon the favorable stockholder vote to approve the final conditions to the closing of the merger.   Any past defaults under the loan agreement have been waived and principal payments on the existing loan will begin September 1, 2013 if the agreement restructuring the loan has not been completed.

 

Product Pipeline

 

Following the completion of the merger, IPI?s product portfolio will consist of the following products:

 

  • Bertilimumab - a first in class monoclonal antibody (mAb) that targets eotaxin-1, a small protein that attracts and activates several sub-classes of immune cells, which are white blood cells that play a role in the development of several inflammatory diseases, including Crohn?s Disease, ulcerative colitis, severe asthma and bullous pemphigoid, a dermatological auto-immune orphan condition with high unmet medical need. Eotaxin-1 has been shown to correlate with the severity of those diseases, which allows for selection of patients based on eotaxin-1 levels, a major step toward treatment personalization. Immune is currently initiating a multi-national Phase II trial of bertilimumab for the treatment of ulcerative colitis, and plans to initiate in late 2013 a Phase II trial for the treatment of bullous pemphigoid.   Data from these trials is expected to report during 2014.

 

  • NanomAbs -   an antibody drug conjugate (ADC) platform designed to deliver cancer drugs specifically to tumor cells thereby improving efficacy and reducing off-target undesirable effects.   Immune intends to continue development of its own candidates as well as to enter into partnerships where it will incorporate the partner?s chemotherapeutic drug into the NanomAbs and/or power the partner?s antibody with a drug-loaded nano-particle.

 

  • AmiKet? -   a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affects more than 15 million people in the U.S.   IPI will continue EpiCept?s efforts to out license the product candidate for Phase III development and commercial marketing for the treatment of chemotherapy-induced peripheral neuropathic pain (CIPN) and possibly other peripheral neuropathies.   AmiKet has obtained Fast Track status for the treatment of CIPN and is eligible for an FDA Special Protocol Assessment.   AmiKet has also been granted orphan drug status for the treatment of post-herpetic neuralgia.

 

  • Crolibulin -   a vascular disruption agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.   In December 2010 the National Cancer Institute initiated a Phase Ib/II trial for crolibulin to assess safety and efficacy in combination with cisplatin in patients with anaplastic thyroid cancer .   The Phase I safety portion of the trial completed in early 2013, and the results were presented at the May 2013 ASCO meeting in Chicago.   Immune believes that crolibulin may be a candidate for use with its NanomAb technology.

 

IPI will have dual headquarters in Herzliya-Pituach, Israel and in the New York City area, with research laboratories in Rehovot, Israel.  Daniel Teper, PharmD, Chief Executive Officer of Immune Pharmaceuticals Ltd., will be IPI?s Chairman and CEO.   Dr. David Sidransky, Director of Head and Neck Research Division, Professor of Oncology at the Johns Hopkins School of Medicine, and a former Vice Chairman of the Board of Directors of ImClone Systems, will be the Vice Chairman of the Board.   The board of directors of the combined company will consist of Dr. Daniel Teper, Dr. David Sidransky, the remainder of the current board of directors of Immune, which consists of Herve de Kergrohen, Isaac Kobrin, Pierre Albouy and Ana Stancic, and Robert W. Cook, EpiCept?s current Interim President, Chief Executive Officer and Chief Financial Officer, who will also serve as the Chief Financial Officer of IPI.   IPI plans to assume EpiCept?s common stock listings on the OTCQX and on the NASDAQ OMX Stockholm Exchange. 

 

Financial and Operating Highlights

 

EpiCept?s net loss attributable to common stockholders for the second quarter of 2013 was $1.7 million, or $0.01 per share, compared with net income attributable to common stockholders of $2.2 million, or $0.03 per share, for the second quarter of 2012.   The net income attributable to common stockholders for the second quarter of 2012 included $0.8 million of deemed dividends on convertible preferred stock.   EpiCept?s net loss attributable to common stockholders for the six months ended June 30, 2013 was $2.8 million, or $0.03 per share, compared with a net loss attributable to common stockholders of $2.5 million, or $0.03 per share, for the six months ended June 30, 2012.   The net loss attributable to common stockholders for the six months ended June 30, 2012 included $1.9 million of deemed dividends on convertible preferred stock.

 

 

 

Second Quarter and Six Months 2013 vs. Second Quarter and Six Months 2012

 

Revenue

The Company recognized revenue of $0.1 million and $6.6 million during the second quarters of 2013 and 2012, respectively.   The Company recognized revenue of $0.5 million and $6.8 million during the six months ended June 30, 2013 and 2012, respectively.   For the second quarter of 2013, revenue consisted primarily of the recognition of license fee payments previously received from the Company?s partners.   For the second quarter of 2012, revenue consisted primarily of license fee payments and product revenue from the sale of the Company?s rights to Ceplene ? to Meda AB.

 

Cost of Goods Sold

Cost of goods sold in the second quarter of 2013 and 2012 was zero and $0.4 million, respectively, consisting solely of the cost for Ceplene ? inventory sold during the quarter.  

 

Selling, General and Administrative (SG&A) Expense

SG&A expense in the second quarter of 2013 decreased by 36%, or $0.5 million, to $0.9 million from $1.4 million in the second quarter of 2012.   The decrease was primarily attributable to lower salary and salary related expenses as the result of a reduction in staff and lower consulting expenses.   SG&A expense in the six months ended June 30, 2013 decreased by 39%, or $1.1 million, to $1.7 million from $2.8 million in the six months ended June 30, 2012.   The decrease was primarily attributable to lower salary and salary related expenses as the result of a reduction in staff and lower consulting expenses.   The Company expects general and administrative expenses to remain at approximately current levels through the close of the merger with Immune.

 

Research and Development (R&D) Expense

R&D expense in the second quarter of 2013 decreased by 30%, or $0.3 million, to $0.7 million from $1.0 million in the second quarter of 2012.   This decrease was primarily related to lower clinical trial expenses in connection with the sale of EpiCept?s rights to Ceplene ? in Europe and certain Pacific Rim countries in June 2012 .   R&D expense in the six months ended June 30, 2013 decreased by 57%, or $1.3 million, to $1.0 million from $2.3 million in the six months ended June 30, 2012.   This decrease was primarily related to lower clinical trial expenses in connection with the sale of EpiCept?s rights to Ceplene ? in Europe and certain Pacific Rim countries in June 2012 and lower salary and salary related expenses as the result of a reduction in staff .   The Company expects R&D expense to remain at approximately current levels through the close of the merger with Immune .

 

Other Income (Expense)

Other income (expense) in the second quarter of 2013 amounted to net expense of $0.2 million compared with net expense of $0.9 million in the second quarter of 2012.   Other income (expense) in the six months ended June 30, 2013 amounted to net expense of $0.4 million compared with net expense of $1.9 million in the six months ended June 30, 2012.   The primary component of other expense in 2013 was interest expense related primarily to the Company?s senior secured term loan.   The primary components of other expense in 2012 were warrant amendment expense of $0.9 million, interest expense of $0.7 million related primarily to the Company?s senior secured term loan and a foreign exchange loss of $0.3 million.

 

 

 

.

 

About EpiCept Corporation

 

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet?, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.   The Company's product Ceplene ? , when used concomitantly with low-dose IL-2, is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.   The Company sold all of its rights to Ceplene ? in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene ? inventory to Meda AB in June 2012.   Ceplene ? is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene ? in all other countries, including countries in North and South America.   The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

 

About Immune Pharmaceuticals Ltd.

 

Immune Pharmaceuticals Ltd. is an Israel- and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics to address unmet medical needs in the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed exclusive worldwide rights to bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the global biologics unit of AstraZeneca. Additionally, Immune has licensed from Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, injectable applications of the antibody nanoparticle conjugate technology (NanomAbs? ) developed by Prof. Shimon Benita.  For more information, visit the Immune website at www.immunepharmaceuticals.com .

 

Forward-Looking Statements

 

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements.   You are urged to consider statements that include the words ?may,? ?will,? ?would,? ?could,? ?should,? ?believes,? ?estimates,? ?projects,? ?potential,? ?expects,? ?plans,? ?anticipates,? ?intends,? ?continues,? ?forecast,? ?designed,? ?goal? or the negative of those words or other comparable words to be uncertain and forward-looking.   Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that we may be unable to complete the proposed merger transaction with Immune Pharmaceuticals Ltd.; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for AmiKet? or crolibulin? will not be successful; the risk that AmiKet?, Azixa ? or crolibulin? will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet? on attractive terms, a timely basis or at all; the risk that Ceplene ? will not receive regulatory approval or marketing authorization in the United States or Canada; the risk that Ceplene ? will not achieve significant commercial success; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.epicept.com . You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.


Selected financial information follows:

EpiCept Corporation and Subsidiaries

 

 

(Unaudited)

 

 

Selected Consolidated Balance Sheet Data

 

 

(in $000s)

 

 

 

June 30,

December 31,

 

2013

2012

 

 

 

Cash and cash equivalents

    $               200

    $               172

Property and equipment, net

36

56

Total assets

$                960

$            1,328

 

 

 

Accounts payable and other accrued liabilities

$            4,801

$            3,512

Deferred revenue

7,662

7,810

Notes and loans payable

4,040

3,975

Total stockholders? deficit

(16,181)

(13,969)

Total liabilities and stockholders? deficit

$                960

$            1,328

 

 

EpiCept Corporation and Subsidiaries

 

 

 

 

(Unaudited)

 

 

 

 

 

Selected Consolidated Statement of Operations Data

 

 

 

(in $000s except share and per share data)

 

 

 

 

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2013

2012

 

2013

2012

 

 

 

 

 

 

Product net revenues

  $                 ?

  $               577

 

  $                283

  $               583

Licensing and other revenues

                    99

               6,025

 

                   192

               6,260

Total revenue

                    99

               6,602

 

                   475

               6,843

Costs and expenses:

                       

                       

 

                        

                       

Cost of goods sold

                    ?

                 396

 

                   143

                  396

Selling, general and administrative

                 927

              1,384

 

               1,737

              2,815

Research and development

                 681

                 963

 

               1,011

              2,259

     Total costs and expenses

               1,608

               2,743

 

                2,891

               5,470

     Income (loss) from operations

             (1,509)

               3,859

 

              (2,416)

               1,373

Other income (expense):

                       

                       

 

                        

                       

Interest income

                    ?

                      1

 

                    ?

                      3

Foreign exchange loss

                    ?

                (521)

 

                    ?

                (264)

Warrant amendment expense

                    ?

                    ?

 

                    ?

                (936)

Interest expense

                (175)

                (380)

 

                  (363)

                 (743)

     Other income (expense), net

                (175 )

                (900 )

 

                  (363)

             (1,940)

Net income (loss) before income taxes

             (1,684)

              2,959

 

              (2,779)

                (567)

Income taxes

                    ?

                    ?

 

                  (5)

                 (2)

Net income (loss )

  $          (1,684)

  $            2,959

 

  $            (2,784)

  $              (569)

Deemed dividends on convertible preferred stock

                    ?

               (750)

 

                      ?

             (1,926)

Income (loss) attributable to common stockholders

  $          (1,684)

  $            2,209

 

  $            (2,784)

  $           (2,495)

 

 

 

 

 

 

Basic and diluted income (loss) per common share

  $            (0.01)

  $               0.03

 

$              (0.03)

$              (0.03)

 

 

 

 

 

 

Weighted average shares - Basic

   113,639,424

     83,772,960

 

  110,158,277

    80,414,692

Weighted average shares - Diluted

   113,639,424

     91,591,893

 

  110,158,277

    80,414,692


 

EpiCept Corporation and Subsidiaries

 

 

(Unaudited)

 

 

Selected Consolidated Statement of Cash Flows Data

 

(in $000s)

 

 

 

 

 

Six Months Ended June 30,

 

2013

2012

 

 

 

Net cash used in operating activities

$     (1,402)

$      (2,599)

Net cash provided by investing activities

308

?

Net cash provided by financing activities  

1,138

1,003

Effect of exchange rate changes on cash

                (16)

                (9)

Net increase (decrease) in cash and cash equivalents            

28

(1,605)

Cash and cash equivalents at beginning of   period

           172

           6,378

Cash and cash equivalents at end of   period

$          200

$          4,773

 

 

EpiCept Corporation and Subsidiaries

 

 

(Unaudited)

 

 

Selected Consolidated Statement of Stockholders? Deficit Data

(in $000s)

 

 

 

 

 

 

Six Months Ended June 30,

 

2013

2012

 

 

 

Stockholders? deficit at beginning of   period

$     (13,969)

$     (17,146)

 

 

 

Net loss for the period

(2,784)

(569)

Stock-based compensation expense

88      

404      

Foreign currency translation adjustment

(16)

257

Share and warrant issuance

500

2,833

Warrant amendment expense

?

936

Exercise of warrants

              ?

            728

 

 

 

Stockholders? deficit at end of   period

$   (16,181)

$   (12,557)

 

As of July 31, 2013, EpiCept had 114,159,030 common shares outstanding .

 

EpiCept expects to report interim results for the three months ending September 30, 2013 on or about November 15, 2013

 

# # #
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 130

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 50

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 75

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 99

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 50

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 49

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 81

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Huawei's Innovative Energy Solutions Drive Renewable Power Growth

Updated Category News Views 184

Transforming Energy Solutions with Huawei Digital Power At a prominent event in Germany, Huawei Digital Power made waves by showcasing cutting-edge solar and energy storage technologies. The company hosted an important launch event under the title "Smart PV & ESS: Powering a Grid Forming Future," emphasizing their commitment to advancing renewable energy solutions. With...

Continue Reading
Carlyle Credit Income Fund's NAV Insights and Latest Developments

Updated Category News Views 225

Understanding Carlyle Credit Income Fund's Latest NAV Report Carlyle Credit Income Fund (NYSE: CCIF) has recently unveiled its unaudited net asset value (NAV) per common share, reporting this figure as $7.64. This information was shared through a filing with the Securities and Exchange Commission, indicating the fund's current fiscal status. The announcement is important...

Continue Reading
Tuya Inc. to Announce Q4 and Fiscal Year 2025 Results Soon

Updated Category News Views 140

Tuya Inc. to Release Financial Results for Q4 and Fiscal Year 2025 Tuya Inc. (NYSE: TUYA), a prominent AI cloud platform service provider, has announced that it will share its fourth quarter and preliminary fiscal year 2025 financial results shortly after the market closes during the first week of March. This is a significant event for the company as it highlights the...

Continue Reading
Geopolitical Tensions Influence Oil Prices: Market Insights

Updated Category News Views 154

Current Oil Market Dynamics Amid Global Tensions Crude prices have shown significant resilience following earlier losses, positioning themselves for a potential third consecutive day of gains. As geopolitical tensions continue to escalate, the latest developments in the Middle East are fueling market reactions. Iran's Potential Military Actions and Market Implications...

Continue Reading
Antimony Market Growth: A Multi-Billion Dollar Future Ahead

Updated Category News Views 221

The Rising Antimony Market: A New Era of Opportunities Antimony minerals, primarily sourced from stibnite and its various forms, play a crucial role in multiple industries due to their unique properties such as flame retardancy and alloy formation. As societies continue to focus on enhancing safety in various applications, particularly in construction and automotive, the...

Continue Reading